These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29736201)

  • 1. Niclosamide ethanolamine improves diabetes and diabetic kidney disease in mice.
    Han P; Shao M; Guo L; Wang W; Song G; Yu X; Zhang C; Ge N; Yi T; Li S; Du H; Sun H
    Am J Transl Res; 2018; 10(4):1071-1084. PubMed ID: 29736201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niclosamide ethanolamine improves kidney injury in db/db mice.
    Han P; Zhan H; Shao M; Wang W; Song G; Yu X; Zhang C; Ge N; Yi T; Li S; Sun H
    Diabetes Res Clin Pract; 2018 Oct; 144():25-33. PubMed ID: 30081104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niclosamide ethanolamine protects kidney in adriamycin nephropathy by regulating mitochondrial redox balance.
    Han P; Yuan C; Wang Y; Wang M; Weng W; Zhan H; Yu X; Wang T; Li Y; Yi W; Shao M; Li S; Yi T; Sun H
    Am J Transl Res; 2019; 11(2):855-864. PubMed ID: 30899385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice.
    Guo J; Tao H; Alasadi A; Huang Q; Jin S
    Eat Weight Disord; 2019 Feb; 24(1):91-96. PubMed ID: 28780747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial uncoupling has no effect on microvascular complications in type 2 diabetes.
    Hinder LM; Sas KM; O'Brien PD; Backus C; Kayampilly P; Hayes JM; Lin CM; Zhang H; Shanmugam S; Rumora AE; Abcouwer SF; Brosius FC; Pennathur S; Feldman EL
    Sci Rep; 2019 Jan; 9(1):881. PubMed ID: 30696927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes.
    Bjornstad P; Singh SK; Snell-Bergeon JK; Lovshin JA; Lytvyn Y; Lovblom LE; Rewers MJ; Boulet G; Lai V; Tse J; Cham L; Orszag A; Weisman A; Keenan HA; Brent MH; Paul N; Bril V; Perkins BA; Cherney DZI
    Diabetes Obes Metab; 2019 Mar; 21(3):575-583. PubMed ID: 30311395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment with niclosamide ethanolamine and artemether combination improves type 1 diabetes via the targeting of liver mitochondria.
    Weng W; Liu H; Sun Z; Zhou P; Yu X; Shao M; Han P; Sun H
    Exp Ther Med; 2022 Mar; 23(3):239. PubMed ID: 35222716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niclosamide ethanolamine inhibits artery constriction.
    Li SL; Yan J; Zhang YQ; Zhen CL; Liu MY; Jin J; Gao JL; Xiao XL; Shen X; Tai Y; Hu N; Zhang XZ; Sun ZJ; Dong DL
    Pharmacol Res; 2017 Jan; 115():78-86. PubMed ID: 27872020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repositioning of niclosamide ethanolamine (NEN), an anthelmintic drug, for the treatment of lipotoxicity.
    Park JS; Lee YS; Lee DH; Bae SH
    Free Radic Biol Med; 2019 Jun; 137():143-157. PubMed ID: 31035006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niclosamide ethanolamine ameliorates diabetes-related muscle wasting by inhibiting autophagy.
    Cai Y; Zhan H; Weng W; Wang Y; Han P; Yu X; Shao M; Sun H
    Skelet Muscle; 2021 Jun; 11(1):15. PubMed ID: 34107998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artemether ameliorates type 2 diabetic kidney disease by increasing mitochondrial pyruvate carrier content in db/db mice.
    Han P; Wang Y; Zhan H; Weng W; Yu X; Ge N; Wang W; Song G; Yi T; Li S; Shao M; Sun H
    Am J Transl Res; 2019; 11(3):1389-1402. PubMed ID: 30972169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-
    Hong Q; Zhang L; Fu J; Verghese DA; Chauhan K; Nadkarni GN; Li Z; Ju W; Kretzler M; Cai GY; Chen XM; D'Agati VD; Coca SG; Schlondorff D; He JC; Lee K
    J Am Soc Nephrol; 2019 Apr; 30(4):546-562. PubMed ID: 30858225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The changes of serum sKlotho and NGAL levels and their correlation in type 2 diabetes mellitus patients with different stages of urinary albumin.
    Wu C; Wang Q; Lv C; Qin N; Lei S; Yuan Q; Wang G
    Diabetes Res Clin Pract; 2014 Nov; 106(2):343-50. PubMed ID: 25263500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes.
    Sekercioglu N; Lovblom LE; Bjornstad P; Lovshin JA; Lytvyn Y; Boulet G; Farooqi MA; Orszag A; Lai V; Tse J; Cham L; Keenan HA; Brent MH; Paul N; Bril V; Perkins BA; Cherney DZI
    Ren Fail; 2019 Nov; 41(1):427-433. PubMed ID: 31162987
    [No Abstract]   [Full Text] [Related]  

  • 15. Four-and-a-Half LIM Domains Protein 2 Is a Coactivator of Wnt Signaling in Diabetic Kidney Disease.
    Li SY; Huang PH; Tarng DC; Lin TP; Yang WC; Chang YH; Yang AH; Lin CC; Yang MH; Chen JW; Schmid-Schönbein GW; Chien S; Chu PH; Lin SJ
    J Am Soc Nephrol; 2015 Dec; 26(12):3072-84. PubMed ID: 25855776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artemether improves type 1 diabetic kidney disease by regulating mitochondrial function.
    Wang Y; Han P; Wang M; Weng W; Zhan H; Yu X; Yuan C; Shao M; Sun H
    Am J Transl Res; 2019; 11(6):3879-3889. PubMed ID: 31312396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of minocycline on microvascular complications in murine models of type 1 and type 2 diabetes.
    Eid SA; O'Brien PD; Hinder LM; Hayes JM; Mendelson FE; Zhang H; Narayanan S; Abcouwer SF; Brosius FC; Pennathur S; Savelieff MG; Feldman EL
    J Transl Sci; 2021 Feb; 7(1):. PubMed ID: 33868719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes.
    Eid SA; O'Brien PD; Hinder LM; Hayes JM; Mendelson FE; Zhang H; Zeng L; Kretzler K; Narayanan S; Abcouwer SF; Brosius Iii FC; Pennathur S; Savelieff MG; Feldman EL
    Biology (Basel); 2020 Oct; 9(11):. PubMed ID: 33105667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients].
    Ma RX; Zhao N; Zhang W
    Zhonghua Nei Ke Za Zhi; 2013 Jun; 52(6):469-73. PubMed ID: 24059992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of and risk factors for the development and progression of diabetic kidney disease.
    Macisaac RJ; Ekinci EI; Jerums G
    Am J Kidney Dis; 2014 Feb; 63(2 Suppl 2):S39-62. PubMed ID: 24461729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.